Back to today’s briefing

Story perspectives

Revolutionary CAR T-Cell Therapy Shrinks Glioblastoma Tumors 62%

6/4/2025

35 6

Summary

Story summary

A groundbreaking dual-target CAR T-cell therapy is making waves in the fight against recurrent glioblastoma, successfully shrinking tumors in 62% of patients. Remarkably, some individuals lived beyond 12 months, defying usual expectations. This innovative treatment targets EGFR and IL-13R?2, delivered through cerebrospinal fluid, with future trials aiming to extend its life-saving effects.

1 of 1

Story summary

A groundbreaking dual-target CAR T-cell therapy is making waves in the fight against recurrent glioblastoma, successfully shrinking tumors in 62% of patients. Remarkably, some individuals lived beyond 12 months, defying usual expectations. This innovative treatment targets EGFR and IL-13R?2, delivered through cerebrospinal fluid, with future trials aiming to extend its life-saving effects.